Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.4x | −4.4x | −0.3x | |
PEG Ratio | −0.24 | −0.06 | 0.00 | |
Price/Book | 138.1x | 3.0x | 2.6x | |
Price / LTM Sales | 3,026.0x | 7.8x | 3.0x | |
Upside (Analyst Target) | 32.8% | 151.2% | 54.6% | |
Fair Value Upside | Unlock | −5.9% | 8.6% | Unlock |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company’s lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.